Efficacy of post exposure administration of doxycycline in a murine model of inhalational melioidosis

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Carl Gelhaus, H ^a   Anderson, Michael S ^a   Fisher, David A ^a   Flavin, Michael T ^b   Xu, Ze Qi ^b,c   Sanford, Daniel C ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b Advanced Life Sciences   (United States)

^c SynChem GMP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DOXYCYCLINE;

AEROSOL; ANIMAL; ARTICLE; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODEL; LD 50; MALE; MELIOIDOSIS; MICROBIOLOGY; MORTALITY; MOUSE; PATHOGENICITY;

AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODELS, ANIMAL; DOXYCYCLINE; LETHAL DOSE 50; MALE; MELIOIDOSIS; MICE;

MLCS; MLOWN;

EID: 84873164873     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01146     Document Type: Article

References (37)

1. Currie, B. J., Dance, D. A. & Cheng, A. C. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg 102 Suppl 1, S1-4 (2008).
2. Wiersinga, W. J., Currie, B. J. & Peacock, S. J. Melioidosis. N Engl J Med 367, 1035-44 (2012).
3. Cheng, A. C. & Currie, B. J. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18, 383-416 (2005). (Pubitemid 40548298)
4. Currie, B. J. & Jacups, S. P. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis 9, 1538-42 (2003).
5. Currie, B. J., Ward, L. & Cheng, A. C. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4, e900 (2010).
6. Ngauy, V., Lemeshev, Y., Sadkowski, L. & Crawford, G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 43, 970-2 (2005). (Pubitemid 40256075)
7. Alibek, K. & Handelman, S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World-Told from Inside by the Man Who Ran It Random House, 1999.
8. Thibault, F. M., Hernandez, E., Vidal, D. R., Girardet, M. & Cavallo, J. D. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54, 1134-8 (2004).
9. Currie, B. J., Fisher, D. A., Anstey, N. M. & Jacups, S. P. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 94, 301-4 (2000). (Pubitemid 30406565)
10. White, N. J. Melioidosis. Lancet 361, 1715-22 (2003).
11. Veljanov, D., Vesselinova, A., Nikolova, S., Najdenski, H., Kussovski, V. & Markova, N. Experimental melioidosis in inbred mouse strains. Zentralbl Bakteriol 283, 351-9 (1996).
12. Leakey, A. K., Ulett, G. C. & Hirst, R. G. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog 24, 269-75 (1998). (Pubitemid 28266810)
13. Hoppe, I., Brenneke, B., Rohde, M., Kreft, A., Haussler, S., Reganzerowski, A. & Steinmetz, I. Characterization of a murine model of melioidosis: comparison of different strains of mice. Infect Immun 67, 2891-900 (1999). (Pubitemid 29244705)
14. Santanirand, P., Harley, V. S., Dance, D. A., Drasar, B. S. & Bancroft, G. J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect Immun 67, 3593-600 (1999). (Pubitemid 29291534)
15. Gauthier, Y. P., Hagen, R. M., Brochier, G. S., Neubauer, H., Splettstoesser, W. D., Finke, E. J. & Vidal, D. R. Study on the pathophysiology of experimental Burkholderia pseudomallei infection in mice. FEMS Immunol Med Microbiol 30, 53-63 (2001). (Pubitemid 32145005)
16. Liu, B. Koo, G. C., Yap, E. H., Chua, K. L. & Gan, Y. H. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun 70, 504-11 (2002). (Pubitemid 34083807)
17. Van Zandt, K. E., Tuanyok, A., Keim, P. S., Warren, R. L. & Gelhaus, H. C. An Objective Approach for Burkholderia pseudomallei Strain Selection as Challenge Material for Medical Countermeasures Efficacy Testing. Front Cell Infect Microbiol 2, 120 (2012).
18. Roy, C. J. & Pitt, M. L. Infectious Disease Aerobiology: Aerosol Challenge Methods. in: J. R. Swearengen, (Ed.), Biodefense Research Methodology and Animal Models, CRC Press, Boca Raton, FL, 2006, pp. 61-76.
19. Lever, M. S., Nelson, M., Stagg, A. J., Beedham, R. J.& Simpson, A. J. Experimental acute respiratory Burkholderia pseudomallei infection in BALB/c mice. Int J Exp Pathol 90, 16-25 (2009).
20. Jeddeloh, J. A., Fritz, D. L., Waag, D. M., Hartings, J. M. & Andrews, G. P. Biodefense-driven murine model of pneumonic melioidosis. Infect Immun 71, 584-7 (2003). (Pubitemid 36026071)
21. Nieves, W., Asakrah, S., Qazi, O., Brown, K. A., Kurtz, J., Aucoin, D. P., McLachlan, J. B., Roy, C. J. & Morici, L. A. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 29, 8381-9 (2011).
22. Tan, G. Y., Liu, Y., Sivalingam, S. P., Sim, S. H., Wang, D., Paucod, J. C., Gauthier, Y. & Ooi, E. E. Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J Med Microbiol 57, 508-15 (2008). (Pubitemid 351537028)
23. Chaowagul, W., Chierakul, W., Simpson, A. J., Short, J. M., Stepniewska, K., Maharjan, B., Rajchanuvong, A., Busarawong, D., Limmathurotsakul, D., Cheng, A. C., Wuthiekanun, V., Newton, P. N., White, N. J., Day, N. P. & Peacock, S. J. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprimsulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 49, 4020-5 (2005).
24. Gelhaus, H. C. Barnewall, R. Cross, J. Lindsay, A. S. & Lockman, H. Qualification of a Mouse Model of Tularemia by Confirming Doxycycline Efficacy, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010.
25. Kenny, D. J., Russell, P., Rogers, D., Eley, S. M. & Titball, R. W. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother 43, 2773-5 (1999).
26. Jenney, A. W., Lum, G., Fisher, D. A. & Currie, B. J. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 17, 109-13 (2001). (Pubitemid 32101565)
27. Fisher, M. W., Hillegas, A. B. & Nazeeri, P. L. Susceptibility in vitro and in vivo of Pseudomonas pseudomallei to rifampin and tetracyclines. Appl Microbiol 22, 13-6 (1971).
28. Hall, W. H. & Manion, R. E. Antibiotic susceptibility of Pseudomonas pseudomallei. Antimicrob Agents Chemother 4, 193-5 (1973).
29. Sarkar-Tyson, M., Smither, S. J., Harding, S. V., Atkins, T. P. & Titball, R. W. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine 27, 4447-51 (2009).
30. Ulrich, R. L., Deshazer, D., Brueggemann, E. E., Hines, H. B., Oyston, P. C. & Jeddeloh, J. A. Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. J Med Microbiol 53, 1053-64 (2004). (Pubitemid 40052485)
31. Nelson, M., Prior, J. L., Lever, M. S., Jones, H. E., Atkins, T. P. & Titball, R. W. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 53, 1177-82 (2004). (Pubitemid 40052471)
32. Hassan, M. R., Pani, S. P., Peng, N. P., Voralu, K., Vijayalakshmi, N., Mehanderkar, R., Aziz, N. A. & Michael, E. Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia.BMCInfect Dis 10, 302 (2010).
33. Currie, B. J., Jacups, S. P., Cheng, A. C., Fisher, D. A., Anstey, N. M., Huffam, S. E. & Krause, V. L. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health 9, 1167-74 (2004). (Pubitemid 39573988)
34. Sivalingam, S. P., Sim, S. H., Jasper, L. C.,Wang, D., Liu, Y. & Ooi, E. E. Pre-and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. J Antimicrob Chemother 61, 674-8 (2008). (Pubitemid 351321146)
35. Craig, W. A. Pharmacodynamics of antimicrobials: general concepts and applications. in: C. H. Nightingale, T. Murakawa, and P. G. Ambrose, (Eds.), Antimicrobial pharmacodynamics in theory and clinical practice., Marcel Dekker, Inc., New York, NY, 2002, pp. 1-22.
36. Newton, P. N., Chaulet, J. F., Brockman, A., Chierakul, W., Dondorp, A., Ruangveerayuth, R., Looareesuwan, S., Mounier, C. & White, N. J. Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrob Agents Chemother 49, 1622-5 (2005).
37. Heine, H. S., Louie, A., Sorgel, F., Bassett, J., Miller, L., Sullivan, L. J., Kinzig-Schippers, M. & Drusano, G. L. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. J Infect Dis 196, 782-7 (2007). (Pubitemid 47293862)